Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Polyclonal heterogeneity: the new norm for secondary clinical resistance to targeted monotherapy in relapsed leukemia?

Wei, A. et. al
The Alfred Hospital, Melbourne, Victoria, Australia
Cancer Discovery (2019)

In this issue, McMahon and colleagues demonstrate that secondary clinical resistance to the FLT3 inhibitor gilteritinib in relapsed acute myeloid leukemia is often polyclonal and commonly mediated by heterogeneous mutations that activate downstream RAS–MAPK pathways. These fi ndings and recent data from others indicate that emergence of multiple clones, each with distinct mechanisms of resistance, is a common finding at secondary failure of single-agent–targeted therapies for relapsed leukemias.

Biological and clinical significance of dysplastic hematopoiesis in patients with newly-diagnosed multiple myeloma
Maia, C. et al
Distinct genetic pathways define pre-leukemic and compensatory clonal hematopoiesis in Shwachman-Diamond syndrome
Kennedy, A, L. et al
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
Choe, S. et. al
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
DiNardo, C. D. et. al